A Translational Study for Locoregional Recurrence of T4 Colon Cancer

NCT ID: NCT06958926

Last Updated: 2025-05-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-14

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The outcome of T4 locally advanced colon cancer is poor when locoregional recurrence occurred. Previous studies had showed that the aggravation of T4 colon cancer is higher than N-positive colon cancer, contributing to staging paradox that outcomes of stage IIB/C are poorer than stage IIIA colon cancer and higher locoregional recurrence of stage IIB/C colon cancer. The phenomenon cannot be explained by radicality, lymph node harvested and adjuvant chemotherapy administration. To elucidate the cancerous aggravation of T4 colon cancer, the investigators should dive into the clinicopathology, metastatic mechanism and cancer biology.

The investigators hypothesize that peritoneal spreading can be one of the metastatic routes of T4 colon cancer; however, few studies have addressed the finding and deserved investigation. Previous research have found that serum epigenetic alterations and cell-free DNA can serve as a prognostic marker for stage II/III colon cancer.

Therefore, the aim of this study is (1) to explore the role of ascites cfDNA as a potential biomolecular marker for locoregional recurrence; (2) to identify the risk factors of locoregional recurrence for T4 colon cancer by correlating biomolecular markers between clinicopathology, epigenomic alterations in blood and ascites.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

T4 Colorectal Cancer Colorectal Cancer Stage III Colorectal Cancer Stage II

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radical surgery for colon and rectum cancer

Radical surgery for colon and rectum cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.

Intervention Type PROCEDURE

Radical surgery for colorectal cancer

Radical surgery for colorectal cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years old
2. Diagnosed as colorectal cancer
3. Undergo radical colectomy or palliative colectomy, not limited to minimally invasive surgery or open surgery

Exclusion Criteria

1. Age\<18 years old
2. Pregnancy
3. Patients with peritoneal dialysis
4. Patients who are unwilling to undergo colorectal surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yu-Tso Liao, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital Hsin-Chu Branch

Yu-Tso Liao

Role: PRINCIPAL_INVESTIGATOR

National Taiwan University Hospital Hsin-Chu Branch

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Taiwan University Hospital Hsin-Chu branch

Hsinchu, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yu-Tso Liao, MD, PhD

Role: CONTACT

886-3667-7600 ext. 1971

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yu-Tso Liao, MD, PhD

Role: primary

+886972654554

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202407175RINC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.